Literature DB >> 8386106

Cysteinyl leukotrienes overproduction and mast cell activation in aspirin-provoked bronchospasm in asthma.

K Sladek1, A Szczeklik.   

Abstract

In order to examine the hypothesis that in aspirin-induced asthma (AIA) cyclooxygenase inhibition is associated with enhanced release of leukotrienes (LTs), we measured urinary leukotriene E4 (LTE4) and 11-dehydro-thromboxane B2 (TXB2) (as a measure of cyclooxygenase production) following challenge with oral aspirin or inhaled methacholine, in 10 AIA patients. We also determined serum tryptase and eosinophilic catonic protein (ECP) levels, in order to evaluate mast cell and eosinophil activation. Urinary LTE4 excretion was increased sevenfold 4-6 h after aspirin challenge, while 11-dehydro-TXB2 decreased gradually reaching 50% baseline levels 24 h after challenge (p < 0.05). This was accompanied by a significant fall in blood eosinophil count at 6 h, and a tendency to a rise in ECP. The intensity of both LTE4 and 11-dehydro-TXB2 responses depended on the dose of aspirin used (p < 0.001, analysis of variance (ANOVA)). The accompanying maximum fall in forced expiratory volume in one second (FEV1) was not correlated with peak LTE4 levels. In contrast to aspirin, methacholine challenge producing comparable bronchial obstruction, did not alter eicosanoid excretion or serum tryptase or ECP levels. In a separate study, lysine-aspirin inhalation challenge was performed in seven AIA patients, four of whom had responded with a rise in serum tryptase to oral aspirin challenge. Challenge with inhaled aspirin led to similar bronchoconstriction as with oral challenge, but non-respiratory symptoms such as scarlet flush or rhinorrhea were absent, and serum tryptase levels remained unchanged.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8386106

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  36 in total

Review 1.  The measurement of leukotrienes in human fluids.

Authors:  J Y Westcott
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

Review 2.  Antileukotrienes and laboratory models of asthma.

Authors:  S C Lazarus
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

3.  The aspirin disease.

Authors:  D Schiavino; E Nucera; A Milani; M Del Ninno; A Buonomo; J Sun; G Patriarca
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

4.  Effect of pranlukast, an oral leukotriene receptor antagonist, on leukotriene D4 (LTD4) challenge in normal volunteers.

Authors:  T C O'Shaughnessy; P Georgiou; K Howland; M Dennis; C H Compton; N C Barnes
Journal:  Thorax       Date:  1997-06       Impact factor: 9.139

5.  Leukotriene Inhibitors in Sinusitis.

Authors:  John W Steinke; Joshua L Kennedy
Journal:  Curr Infect Dis Rep       Date:  2012-01-29       Impact factor: 3.725

Review 6.  Safety considerations in treating concomitant diseases in patients with asthma.

Authors:  L W Hunt
Journal:  Drug Saf       Date:  1998-05       Impact factor: 5.606

7.  Effect of endobronchial aspirin challenge on inflammatory cells in bronchial biopsy samples from aspirin-sensitive asthmatic subjects.

Authors:  S Nasser; P E Christie; R Pfister; A R Sousa; A Walls; M Schmitz-Schumann; T H Lee
Journal:  Thorax       Date:  1996-01       Impact factor: 9.139

8.  Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma.

Authors:  A S Cowburn; K Sladek; J Soja; L Adamek; E Nizankowska; A Szczeklik; B K Lam; J F Penrose; F K Austen; S T Holgate; A P Sampson
Journal:  J Clin Invest       Date:  1998-02-15       Impact factor: 14.808

9.  Selenium status is decreased in patients with intrinsic asthma.

Authors:  J Kadrabová; A Mad'aric; Z Kovaciková; F Podivínsky; E Ginter; F Gazdík
Journal:  Biol Trace Elem Res       Date:  1996-06       Impact factor: 3.738

Review 10.  Update on recent advances in the management of aspirin exacerbated respiratory disease.

Authors:  Nami Shrestha Palikhe; Joo-Hee Kim; Hae-Sim Park
Journal:  Yonsei Med J       Date:  2009-12-18       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.